Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Why these gold mining stocks could soar

If you hold gold mining stocks in your portfolio, you’re probably a little miffed at the moment. While the Dow Jones Industrial Average lost 1,880 points between July 21 and the morning of August 11, the price of gold shot up 10.5 percent. And that includ...
Matthew Carr | October 28, 2012 |

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Can the Efforts to Turn S&P 500 Around Really Stick?

While Friday’s session turned out kind of undecided, it was still a down session with the bears bringing home the bacon. Can the same conclusion be reached when examining the weekly chart? And what about other valuable clues as to the upcoming S&P 500 move? ...
Monica Kingsley | April 6, 2020 |

Krill oil boom is real

There’s a new type of oil that’s causing a major stir in the markets. This oil boom has nothing to do with crude oil or energy though. But it still has the potential to be just as profitable. I’m talking about krill oil. ...
Andrew Mickey | October 28, 2012 |

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance

Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. Yesterday afternoon, specialty pharmaceutic...
Streetwise Reports | November 7, 2019 |

FDA Approval of Peanut Allergy Treatment Expected Next Year

The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. In a Nov. 7 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that with respect to Aimmune Therapeutics Inc. (AIMT:NASDAQ) , "all eyes r...
Streetwise Reports | November 14, 2019 |

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%

Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. Prior to the U.S. markets open this morning on the first day of trading in 2020, clinical...
Streetwise Reports | January 3, 2020 |

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. Ocular Ther...
Streetwise Reports | March 5, 2020 |

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. ...
Streetwise Reports | March 18, 2020 |
1 2